The molecular and cellular biology of thrombopoietin: the primary regulator of platelet production.
about
A critical role for the transcription factor Scl in platelet production during stress thrombopoiesisMegakaryocyte- and megakaryocyte precursor-related gene therapiesStem cell autotomy and niche interaction in different systemsDecreased prothrombotic effects of pegylated recombinant human megakaryocyte growth and development factor in thrombocytopenic state in a rat thrombosis modelAnalysis of thrombocyte development in CD41-GFP transgenic zebrafish.Autoimmune thrombocytopenia in chronic myeloid leukemia treated with interferon-alpha: differential diagnosis and possible pathogenesis.Differential requirements for the activation domain and FOG-interaction surface of GATA-1 in megakaryocyte gene expression and developmentThe biogenesis of platelets from megakaryocyte proplatelets.Haematopoietic stem and progenitor cell-targeted therapies for thrombocytopenia.Plant sterols cause macrothrombocytopenia in a mouse model of sitosterolemia.Preclinical activity of eltrombopag (SB-497115), an oral, nonpeptide thrombopoietin receptor agonist.Pharmacodynamics and pharmacokinetics of the novel thrombopoietin mimetic peptide RWJ-800088 in humans.The OTT-MAL fusion oncogene activates RBPJ-mediated transcription and induces acute megakaryoblastic leukemia in a knockin mouse model.New advances in the treatment of adult chronic immune thrombocytopenic purpura: role of thrombopoietin receptor-stimulating agents.Considerations in the management of hepatitis C virus-related thrombocytopenia with eltrombopag.Clinical pharmacokinetics, platelet response, and safety of eltrombopag at supratherapeutic doses of up to 200 mg once daily in healthy volunteers.Eltrombopag for the treatment of idiopathic thrombocytopenic purpura.Dasatinib enhances megakaryocyte differentiation but inhibits platelet formation.Nonclinical safety assessment of a synthetic peptide thrombopoietin agonist: effects on platelets, bone homeostasis, and immunogenicity and the implications for clinical safety monitoring of adverse bone effects.Prolonged remission from eltrombopag in chronic refractory idiopathic thrombocytopenic purpura.Low or undetectable TPO receptor expression in malignant tissue and cell lines derived from breast, lung, and ovarian tumors.2-(trimethylammonium)ethyl (R)-3-methoxy-3-oxo-2-stearamidopropyl phosphate promotes megakaryocytic differentiation of myeloid leukaemia cells and primary human CD34⁺ haematopoietic stem cells.High doses of romiplostim induce proliferation and reduce proplatelet formation by human megakaryocytes.Eltrombopag for the treatment of thrombocytopenia in patients with malignant and non-malignant hematologic disorders.The role of eltrombopag in the management of hepatitis C virus-related thrombocytopenia.The pharmacology and clinical application of thrombopoietin receptor agonists.Eltrombopag for treatment of thrombocytopenia-associated disorders.The Eltrombopag antitumor effect on hepatocellular carcinoma.Advances in the pathophysiology of primary immune thrombocytopenia.Establishment of a congenital amegakaryocytic thrombocytopenia model and a thrombocyte-specific reporter line in zebrafish.Safety, Pharmacokinetics and Pharmacodynamics of Hetrombopag Olamine, a Novel TPO-R Agonist, in Healthy Individuals.Ubiquitination and degradation of the thrombopoietin receptor c-Mpl.Suppressor screen in Mpl-/- mice: c-Myb mutation causes supraphysiological production of platelets in the absence of thrombopoietin signaling.New roles for cyclin E in megakaryocytic polyploidization.Identification of the residues in the extracellular domain of thrombopoietin receptor involved in the binding of thrombopoietin and a nuclear distribution protein (human NUDC).Megakaryocytes and beyond: the birth of platelets.Platelets as delivery systems for disease treatmentsThrombopoietin complements G(i)- but not G(q)-dependent pathways for integrin {alpha}(IIb){beta}(3) activation and platelet aggregation.Increased differentiation of dermal mast cells in mice lacking the Mpl gene.Control of megakaryocyte expansion and bone marrow fibrosis by lysyl oxidase.
P2860
Q24292976-69EAC08A-BE99-48A5-8E31-EF71BBEDDCBBQ26770867-ABA0A0A5-ACEC-4565-821B-DD64EFB06F52Q26799282-BF0DDE22-9946-46B1-BBD0-F337FF64AE09Q28571052-4873DB2B-7408-47C9-A5A2-2729808598B7Q30796563-99847CF6-5FC4-4A39-8950-AE5BF3ADB0EEQ33359521-D97C3B26-8993-448A-A604-1BC46FC3E18BQ33366025-4D8960E5-33B0-448E-8D06-CB7CC09C30C0Q33369405-11720072-5603-4294-A9D7-FE0BFD1C76C2Q33372720-DF43EC53-655A-49DB-9758-4F3150C0D3E5Q33378034-B1B4B22A-21D2-4DE5-918F-2F376692C5A5Q33382190-6AA3FC2B-43A9-40CD-93E1-BA4588268E41Q33383425-29B257F2-207A-4F19-9C35-401A8A4E52CEQ33383707-CD3EE999-2A9F-4711-A19D-5ED56C514EACQ33387735-8D940E6D-073D-47D4-858D-17DC7EF44147Q33387808-52F5EE9E-F439-4B16-B022-9D61AD7DC42EQ33389284-74A3454A-7866-4048-ADE9-C8639DE2C5D4Q33392852-D7F924A9-5F23-472D-B0DC-F73AFB0119EFQ33394424-91913711-8A12-4A9A-B816-DBA23B402BBDQ33396650-650C4451-577E-46BB-8CC8-C17E2D1E6735Q33402617-FE940F54-3BBD-45F6-AA08-D9DA9CA71575Q33403234-2CEED216-5F18-4AF9-AF03-D8D414F3F882Q33404462-6DBC9661-8085-4EEA-BA7D-6A536625D102Q33405562-7C76910B-D6FE-4321-8D5A-215829A2A73BQ33411387-19F04173-116F-4F98-845A-C68ECFCDAB2BQ33414386-5FE7A8FB-4E15-4C01-9F5E-4318E9F32FABQ33417700-8D107798-82E0-4FA4-A70C-8D2C03B372DFQ33425805-E8859F4E-7C56-4815-B221-1957D5802294Q33426135-50EFA121-D292-4497-9A72-4F47EF20CED6Q33435590-F6FEAB85-8E5D-4026-81A1-32E82421BD41Q33436518-0FB8F438-49E6-4A1C-BEAF-192893DD7659Q33442131-62AB337A-47F2-4012-A662-7BFC7EF8B570Q33677470-27984338-1A28-4432-8213-1A426A8515D5Q33695715-A71F6ADD-67C8-456D-AEAC-48858B49D90BQ33897984-9F0B5910-FD85-4C1C-8CE6-73427101105EQ34074510-351DCFC3-27CC-4AB8-B5B3-AA05CBA26AC0Q34215516-4159EE77-54A1-4A5E-BF7A-7552D8EE7E29Q34348837-7A8AD823-AC8C-4A6F-B262-B7E9F99E5867Q34415047-B023386C-14E0-479C-A120-506E97D61089Q35101887-BF0BAF52-CC9F-493A-8B2D-7BA8AF2DD22CQ35144992-E5F3B501-72CB-4F45-9B06-CA562B5A97E5
P2860
The molecular and cellular biology of thrombopoietin: the primary regulator of platelet production.
description
2002 nî lūn-bûn
@nan
2002 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
The molecular and cellular bio ...... ulator of platelet production.
@ast
The molecular and cellular bio ...... ulator of platelet production.
@en
The molecular and cellular bio ...... ulator of platelet production.
@nl
type
label
The molecular and cellular bio ...... ulator of platelet production.
@ast
The molecular and cellular bio ...... ulator of platelet production.
@en
The molecular and cellular bio ...... ulator of platelet production.
@nl
prefLabel
The molecular and cellular bio ...... ulator of platelet production.
@ast
The molecular and cellular bio ...... ulator of platelet production.
@en
The molecular and cellular bio ...... ulator of platelet production.
@nl
P356
P1433
P1476
The molecular and cellular bio ...... ulator of platelet production.
@en
P2093
Jonathan G Drachman
Kenneth Kaushansky
P2888
P304
P356
10.1038/SJ.ONC.1205323
P407
P577
2002-05-01T00:00:00Z
P5875
P6179
1009611404